Xcout Intel
Hubble Therapeutics, LLC
Hubble Therapeutics is a patient-focused biotechnology company based in New Hampshire that advances gene therapy to treat LCA16, a rare form of childhood blindness.
Subscribe to see Hubble Therapeutics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Hubble Therapeutics, LLC at a glance
Hubble Therapeutics, LLC is a biotechnology company headquartered in United States. It has raised at least $17.1M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $7.3M in March 2025. Xcout tracks 5 named people at Hubble Therapeutics, LLC, including Jeff Sabados (Chief Executive Officer).
Hubble Therapeutics, LLC leadership
- Jeff SabadosChief Executive Officer
- Bikash Pattnaikscientific co-founder
- Jeff SabadosExecutive Officer
- Greg KeenanDirector
- Sam GoldbergerDirector
Hubble Therapeutics, LLC funding rounds
At least $17.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $7.3M | 1 named | |
| SEC Form D filing | $9.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Hubble Therapeutics, LLC competitors
A few of Hubble Therapeutics, LLC's closest competitors — see the full list of competitors and alternatives →
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Get Hubble Therapeutics, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Hubble Therapeutics, LLC? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Hubble Therapeutics, LLC in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access